Amphastar Pharmaceuticals (AMPH) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amphastar Pharmaceuticals (AMPH) has outperformed MannKind (MNKD) over the past year, losing 1.1% versus a loss of 38.9%. Over five years, AMPH leads with a +33.6% price change compared with -32.2% for MNKD. MannKind is the larger company by market cap ($1.10 billion vs $1.10 billion), about 1.0 times the size.
On valuation, Amphastar Pharmaceuticals trades at a lower forward P/E (8.1x vs 26.8x for MannKind).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | MNKD |
|---|---|---|
| Share price | $25.81 | $3.42 |
| Market cap | $1.10B | $1.10B |
| 1-day change | +1.06% | -0.87% |
| YTD return | -4.63% | -39.15% |
| 1-year return | -1.12% | -38.94% |
| 5-year return | +33.65% | -32.22% |
| P/E ratio (TTM) | 15.27 | — |
| Forward P/E | 8.11 | 26.82 |
| EPS (TTM) | $1.69 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.52 | $6.51 |
| 52-week low | $16.65 | $2.23 |
| Distance from 52-week high | -12.57% | -47.47% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -12.82% | +129.24% |
| Average volume | 472.61K | 4.48M |
| Shares outstanding | 42.54M | 321.54M |
| Employees | 1,976 | 591 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMPH has outperformed MNKD by 37.8 percentage points over the past year.
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
AMPH vs MNKD FAQ
Which is bigger, Amphastar Pharmaceuticals or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.10B compared with $1.10B for Amphastar Pharmaceuticals (AMPH).
Which stock has performed better over the past year, AMPH or MNKD?
AMPH returned -1.12% over the past 12 months, compared with -38.94% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are Amphastar Pharmaceuticals and MannKind in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.